drugset / Trial / NCT05201001
APX005M in Patients With Recurrent Ovarian Cancer
Phase 2
Withdrawn
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Belgian Gynaecological Oncology Group · collabGSO Global Clinical Research BV · collabSwiss GO Trial Group · collabThe Central and Eastern European Gynecologic Oncology Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The overall objective is to demonstrate preliminary efficacy of APX005M-carboplatin-PLD and APX005M-radiotherapy-carboplatin-PLD combinations as treatment for relapsed BRCAwt ovarian cancer patients, where platinum combination therapy is an option.
Timeline
- Start
- 2023-09-07
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
Outcome
Outcome not reported
Stopped: “IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sotigalimab | Monoclonal antibody | 0.3 mg/kg | Intravenous |